Business Description

TransMedics Group Inc. is a U.S.-based health care company founded in 2008 that markets the innovative Organ Care System (OCS), a portable organ perfusion system designed to improve transplant outcomes. The company earns revenue from hardware sales and recurring consumable services provided to hospitals and transplant centers. Led by CEO Dr. Christopher J. Love, TransMedics has captured an estimated 15-20% share of the U.S. organ perfusion market while expanding its clinical footprint. Its future initiatives include launching additional organ modules and entering international markets to drive further growth.

Everything on TransMedics Group Inc.

Revenue (FY2025) $605M
YoY growth +37.1%
Operating margin 17.9%
Direction Expanding
Gross margin 59.9%
Net margin 31.4%

Earnings Transcripts

View all transcripts ↗

Named Competitors

OrganOx LimitedXVIVO Perfusion ABParagonix Technologies, Inc.

Recent SEC Filings

2026-05-21 Shareholder vote results View filing ↗
2026-05-05 Reported quarterly results View filing ↗
2026-02-27 Reported quarterly results View filing ↗
2026-02-24 Reported quarterly results View filing ↗
2026-02-04 Leadership change (directors/officers) View filing ↗
2026-01-12 Entered a material agreement (+1 more) View filing ↗
2025-10-29 Reported quarterly results View filing ↗
2025-10-06 Completed an acquisition or disposition View filing ↗
2025-07-30 Reported quarterly results View filing ↗
2025-05-23 Shareholder vote results View filing ↗
2025-05-08 Reported quarterly results View filing ↗
2025-02-27 Reported quarterly results View filing ↗

More Companies

See how VectorShift works for your firm

Request Demo